Outcomes of allogeneic hematopoietic stem cell transplantation for lymphomas: a single-institution experience.

Abstract

INTRODUCTION:

Allogeneic hematopoietic stem cell transplantation offers the opportunity for extended survival in patients with Hodgkin's and non-Hodgkin lymphomas who relapsed after, or were deemed ineligible for, autologous transplantation. This study reports the cumulative experience of a single center over the past 14 years aiming to define the impact of patient, disease, and transplant-related characteristics on outcomes.

METHODS:

All patients with histologically confirmed diagnosis of Hodgkin's or non-Hodgkin lymphomas who received allogeneic transplantation from 2000 to 2014 were retrospectively studied.

RESULTS:

Forty-one patients were reviewed: 10 (24%) had Hodgkin's and 31 (76%) had non-Hodgkin lymphomas. The median age was 50 years and 23 (56%) were male. The majority of patients (68%) had had a prior autologous transplantation. At the time of allogeneic transplantation, 18 (43%) patients were in complete and seven (17%) were in partial remission. Most (95%) patients received reduced-intensity conditioning, 49% received matched sibling donor grafts, 24% matched-unrelated donor grafts, and 27% received double umbilical cord blood grafts. The 100-day treatment-related mortality rate was 12%. After a median duration of follow up of 17.1 months, the median progression-free and overall survival was 40.5 and 95.8 months, respectively. On multivariate analysis, patients who had active disease at the time of transplant had inferior survival.

CONCLUSIONS:

Allogeneic transplantation results extend survival in selected patients with relapsed/refractory Hodgkin's and non-Hodgkin lymphomas with low treatment-related mortality. Patients who have active disease at the time of allogeneic transplantation have poor outcomes.

• Authors: Mira Romany Massoud, Paolo Fabrizio Caimi, Nicole Ferrari, Pingfu Fu, Richard Creger, Robert Fox, Joanne Carlson-Barko, Merle Kolk, Lauren Brister, Brenda Wimpfheimer Cooper, Stanton Gerson, Hillard Michael Lazarus, Marcos de Lima, Basem Magdy William
• Journal: Revista brasileira de hematologia e hemoterapia (Rev Bras Hematol Hemoter) 2016 Oct - Dec Vol. 38 Issue 4 Pg. 314-319 ISSN: 1516-8484 [Print] Brazil
• PMID: 27863759 (Publication Type: Journal Article)
• Copyright: Copyright © 2016 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. All rights reserved.